Asia s Premier Partnering Event for the Biotechnology Industry. Makoto TANIHARA ICS Convention Design, Inc.

Transcription

1 Asia s Premier Partnering Event for the Biotechnology Industry Makoto TANIHARA ICS Convention Design, Inc. February

2 Overview Event Outline BioJapan World Business Forum- Date: October 9 (Wed.)- 11 (Fri.), 2013 Venue: Pacifico YOKOHAMA *YOKOHAMA is a port city in Kanagawa prefecture just 30 minutes away from the center of Tokyo Organizer: BioJapan Organizing Committee including, Japan Bioindustry Association Japan Pharmaceutical Manufacturers Association ICS Convention Design, Inc. <Photo highlights 2012> 1

3 Overview About BioJapan BioJapan provides you an opportunity to meet with 700+ biotech and life science companies in Yokohama. Business development teams from almost all global and Japanese pharma companies will gather in Yokohama for the 15 th BioJapan. The 2013 event will consist of Partnering, Exhibition and Seminars. Partnering Synergy Exhibition Seminars 2

4 Overview BioJapan 2013 Floor Layout *Subject to change Annex Hall *Seminars Exhibition Hall *Partnering Area, Exhibition and 40 Sessions in Total with 5,000+ audiences! 100+ Sessions on Up-to-date Seeds! Seminars /10,000m2 Keynote Speech Organizer s Seminars Luncheon Seminars Sponsored Seminars Exhibitor s Presentations Academic Seeds Presentations Global Partnering Seminar Pacifico Yokohama 3

5 Overview BioJapan 2012 highlights Partnering: 541 companies / 868 delegates from 22 countries 3,372 one-to-one meetings Exhibition: 434 exhibitors / 351 booth stands from 18 countries 12,369 visitors from 27 countries Seminars: 21 Organizer's seminars 18 Sponsored seminars 112 Company presentations 4

6 Partnering Participating Companies at BioJapan 2012 Japanese Pharma Ajinomoto, Astellas, Chugai Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Eisai, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida Pharmaceutical, Nippon Kayaku, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takara Bio, Taisho Pharmaceutical. Takeda, Teijin Pharma, Zeria Pharmaceutical and others. *Almost all Japanese pharma companies participated in Bio Cluster in Japan Kurume Cutting-egde Medical Research Center, Metropolitan Bio Network, Northern Advancement Center for Science & Technology, Osaka Bio Headquarter, Hokuriku Industrial Advancement Center and others. *Approx. 150 Japanese biotech companies participated in

7 Partnering Participating Companies at BioJapan 2012 Global Pharma (without Japanese pharma) AstraZeneca, Baxter, Bristol-Myers Squibb, Eli Lilly (Japan), F. Hoffmann-La Roche, GlaxoSmithKline, Janssen Pharma, MSD, (Nippon) Boehringer Ingelheim, Novartis, Pfizer and Sanofi. Other companies DuPont, Fujifilm Corporation, Kaneka, Kao Corporation, Mitsubishi Chemical Corporation, Roche Diagnostics, Shiseido, Sumitomo Chemical, Teijin Group, Toray and others. Governmental Agencies AIST- National Institute of Advanced Industrial Science and Technology, JST- Japan Science and Technology Agency, Organization for Small & Medium Enterprises and Regional Innovation, RIKEN and others Academics Keio University, Kyoto University, Osaka University, Tokyo Institute of Technology, Tsukuba University, University of Tokyo and others. 6

8 Partnering Online Partnering System The BioJapan matching system is available and the system will enable you to pre-arrange meetings prior to the event. Create new partnerships and strengthen existing business relationships using the system! <Before the event> <At the BioJapan> The 2013 BioJapan partnering is expected to attract 700+ companies. 7

9 Partnering Registration fee Registration fee: JPY50,000 (taxes included) per person *EUR (Based on EUR1.00=JPY125.00) or USD (Based on USD1.00=JPY90.00) Your registration fee covers: Access to the BioJapan matching (partnering) system Access to the exhibition & annex hall and partnering area Lunch for all 3 days at the partnering area Wednesday Welcome Reception Thursday Partnering Party (NEW) 14-minute presentation in the exhibition hall will be available at the extra fee of JPY105,000 (EUR or USD1,150.00). 8

10 Exhibition General information Opportunity to promote your products and services to qualified participants, especially to participants from pharmaceutical companies! Exhibition Categories -Drug and Drug discovery (Small-molecule drug, biologics and vaccine etc.) -Drug Discovery support and contract services (Drug synthesis services, Analysis contract services and Chemical compound libraries and screening etc.) -Medical treatment, Diagnosis and Medical devices and equipments (Biomarkers and Gene therapy etc.) -Research Devices, Reagents and Facilities (Research Devices, Bioinformatics and Bioimaging etc.) -Others (Functional Food, Agriculture, Bio-cluster, Universities and Government Agencies etc.) Specific Theme Zones in Alliance zone (for Pharmaceutical Companies) -Regenerative Medicine Zone -Drug Development Services Zone -In-Silico Drug Discovery Zone 9

11 Exhibition Exhibition Fees and Exhibitor Benefits Exhibition Fees: Booth space per 9 sqm: Early bird: JPY420,000 *EUR3,360 Regular: JPY472,500 *EUR3,780 9 sqm Shell Scheme Booth Early bird based: JPY525,000 *EUR4,200 4 sqm Shell Scheme Booth: JPY199,500 *EUR1,600 Exhibitor Benefits: 1) Partnering account(s) will be provided according to your booth space. 2) Company name listed in the BioJapan 2013 official guidebook 3) Company Directory listing on BioJapan 2013 website For details, see exhibitor prospects Save EUR420 per 9sqm! <Bavarian pavilion at BJ 2012> 10

12 Seminars Organizer's seminars Seminars will consist of Keynote speech, Sponsored Seminars, Exhibitor Presentations, Academic Seeds Presentations and Global Partnering Seminars. The followings were the major themes of 2012 Organizer s seminar. The details for 2013 to be announced. Medicine and Pharmaceuticals including Personalized medicine and Regenerative medicine Healthcare Food and the Agriculture and Fishery Industries Environment and Energy The Foundation of Biotechnology-based Industry 11

13 Seminars Company Presentations BioJapan 2013 invites exhibitors to present at the conference. Sponsored Seminar in the Annex hall (Venue: A private room) Luncheon Seminar: JPY1,260,000 (EUR10,080) per 60 minutes Sponsored Seminar: JPY630,000 (EUR5,040) per 60 minutes Note: The above cost does NOT include the simultaneous interpretation service. Exhibitor Presentation in the exhibition hall (Venue: A presentation venue) For 9 sqm or more exhibitors: JPY262,500 (EUR2,100) per 30 minutes For 4 aqm exhibitors: JPY105,000 (EUR840) per 30 minutes For Academic Laboratories and TLO: JPY42,000 (EUR336) per 30 minutes Note: The above cost does NOT include the simultaneous interpretation service. <Sponsored Seminar> <Exhibitor Presentation> 12

14 Market Business Opportunities in Japan Japan is currently the second-largest pharmaceuticals market in the world with growing demand for drugs due to high life expectancy and an aging population. Total ethical drug sales in Japan based on NHI price levels *Unit: Billion USD Source: IMS Japan Continued to grow * YEAR(JAN-DEC) Japanese TOP 10 pharmaceutical companies based on FY2012 sales figures *Unit: Billion USD Company *Participated in the BioJapan 2012 partnering Sales Figures Source: MR Biz Operating R&D *2 profits Spender Takeda* Astellas Pharma* Daiichi Sankyo* Otsuka pharmaceutical* Eisai* Mitsubishi Tanabe Pharma* Chugai pharmaceutical* Dainippon Sumitomo Pharma* Kyowa Hakko Kirin* Taisho Pharmaceutical* *1: Total ethical drug sales 2011 in Japan based on NHI price levels were approximately billion USD. *Based on exchange rates: USD1.00 = JPY *2: Total R&D spender 2012 of Japanese top 10 pharmaceutical companies were approximately billion USD. *Based on exchange rates: USD1.00 = JPY82.00, 13

15 Market (Summary) Japanese Outbound M&A deals Japanese pharmaceutical companies become more global and strengthen their pipelines by using M&A. Company Takeover candidate Deal Value US $ Date Takeda (Japan) LigoCyte Pharmaceuticals, Inc. (US) 492 million Nov Takeda (Japan) URL Pharma (US) 800 million Apr Asahi Kasei (Japan) Zoll Medical (US) 2.21 billion Mar Dainippon Sumitomo (Japan) Boston Biomedical Inc.(US) 200 million Feb Takeda (Japan) Intellikine (US) 190 million up front plus 120 million in Dec contingent milestones Fujifilm (Japan) SonoSite (US) 995 million Dec Santen Pharma (Japan) Novagali (France) 135 million (50.55% of the shares) Oct Takeda (Japan) Nycomed (Switzerland) 3.68 billion Sep Astellas (Japan) and Maxygen (US) Perseid Therapeutics (US) 76 million May 2011 Takeda (Japan) Fate Therapeutics (US) Undisclosed ( Unspecified stake) May 2011 Kyowa Hakko Kirin (Japan) ProStrakan (UK) 474 million Apr Daiichi Sankyo (Japan) Plexxikon (US) 805 million Apr Nitto Denko (Japan) Avecia Biotech (US) Undisclosed Feb Zeria pharmaceutical (Japan) Biofac Esbjerg A/S (Denmark) million (85% of the shares) Sep KANEKA (Japan) Eurogentec(Belgium) 45 million Jul Astellas (Japan) OSI Pharmaceuticals 4.00 billion Mar Eisai (Japan) AkaRx (US) 255 million Jan

16 Market (Summary) Drug Discovery Collaboration Japanese pharmaceutical companies are seeking partners in order to accelerate drug development and make more efficient use of precious capital. Company Partner Release date Otsuka Pharmaceutical (JPN) Living Cell Technologies Limited (Australia) Dec Takeda (JPN) Advinu (India) Oct Ono Pharmaceutical (JPN) Domain Therapeutics S.A. (France) Oct Takeda (JPN) The BC Cancer Agency (Canada) Aug, 2012 Daiichi Sankyo (JPN) NGM Biopharmaceuticals, Inc. (US) Mar Teijin Pharma (JPN) NovAliX (France) Jan Astellas (JPN) and Agensys, Inc. (US) Seattle Genetics, Inc.(US) Jun Eisai(JPN) UCL (UK) May 2011 Takeda (JPN) Heptares Therapeutics (UK) Apr Takeda (JPN) Samyang Corporation (S. Korea) Apr Daiichi Sankyo (JPN) Pieris AG (Germany) Apr Eisai(JPN) Epizyme, Inc.(US) Mar Astellas (JPN) Cell Signaling Technology, Inc.(US) Feb Ono Pharmaceutical (JPN) BioFocus(UK) Jan Eisai(JPN) FORMA Therapeutics (US) Nov Ono Pharmaceutical (JPN) BioSeek (US) Mar It s said that BioJapan is the best partnering event in Japan and provides you a great opportunity to meet pharma professionals. 15

17 Market Japanese Biotech IPOs The number of Japanese biotech IPOs (yearly, ) Japanese Biotech IPOs in 2011 and 2012 Company Market IPO date Eugrena Tokyo Stock Exchange Mothers Dec UMN Pharma Tokyo Stock Exchange Mothers Dec GENE TECHNO SCIENCE Tokyo Stock Exchange Mothers Nov CHIOME Biosceiece Tokyo Stock Exchange Mothers Dec SymBio Pharmaceutical Osaka Securities Exchange JASDAQ Growth Market Oct D Matrix Osaka Securities Exchange JASDAQ Growth Market Oct RaQualia Pharma Osaka Securities Exchange JASDAQ Growth Market Jul Mebiopharm Tokyo AIM Jul Hit a new record high in 2011 but many biotech companies will be forced to shut down due to lack of funding. 16

18 CONTACT Makoto Tanihara / Global Event Manager ADDRESS: Chiyoda Bldg., Sarugaku-cho, Chiyoda-ku, Tokyo Japan PHONE: / FAX: biojapan@ics-inc.co.jp Website: Thank you for your interest in BioJapan and I look forward to seeing you all in Japan. 17